Head to Head Analysis: Bioqual (OTCMKTS:BIOQ) vs. RadNet (NASDAQ:RDNT)

Bioqual (OTCMKTS:BIOQ) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Profitability

This table compares Bioqual and RadNet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioqual	-4.34%	-5.82%	-3.79%
RadNet	-0.78%	2.41%	0.82%

Volatility & Risk

Bioqual has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Bioqual and RadNet, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioqual	0	0	0	0	0.00
RadNet	0	1	4	3	3.25

RadNet has a consensus price target of $76.80, indicating a potential upside of 2.97%. Given RadNet’s stronger consensus rating and higher probable upside, analysts plainly believe RadNet is more favorable than Bioqual.

Insider and Institutional Ownership

77.9% of RadNet shares are held by institutional investors. 39.2% of Bioqual shares are held by company insiders. Comparatively, 5.6% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Bioqual and RadNet”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioqual	$58.59 million	0.61	$480,000.00	($2.39)	-16.74
RadNet	$1.91 billion	3.01	$2.79 million	($0.20)	-372.93

RadNet has higher revenue and earnings than Bioqual. RadNet is trading at a lower price-to-earnings ratio than Bioqual, indicating that it is currently the more affordable of the two stocks.

Summary

RadNet beats Bioqual on 13 of the 15 factors compared between the two stocks.

About Bioqual

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

About RadNet

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.